Physician profile
Blake Galler
NPI 1265705933
$6,958.45
in general payments reported to CMS, 2019-2025
39 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.21 · 2022: $1,889 · 2023: $1,344 · 2024: $2,121 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,438 · Education: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,438.34 |
| Education | $579.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teladoc Health, INC. | $1,425.00 | 2022 | |
| Janssen Biotech, INC. | $1,083.22 | 2023-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $767.09 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $586.44 | 2022-2025 | Otezla, Repatha, Tavneos |
| Arcutis Biotherapeutics, INC. | $556.20 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $360.83 | 2022-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $343.81 | 2023-2025 | |
| Abbvie INC. | $212.57 | 2022-2025 | |
| Leo Pharma INC. | $183.72 | 2024-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $169.54 | 2022-2025 | Aklief, Nemluvio |
| Astrazeneca Pharmaceuticals LP | $135.20 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Dermavant Sciences, INC. | $114.39 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $106.21 | 2022-2025 | |
| Genzyme Corporation | $95.39 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.82 | 2022-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $80.16 | 2022-2023 | Wegovy, Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $76.47 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Blueprint Medicines Corporation | $57.30 | 2024-2025 | Ayvakit |
| Merz North America, INC. | $44.69 | 2023-2025 | |
| Organon LLC | $44.57 | 2025 | |
| Organogenesis INC. | $36.48 | 2023-2024 | Puraply |
| Takeda Pharmaceuticals U.S.A., INC. | $31.70 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.71 | 2022 | |
| Dexcom, INC. | $29.65 | 2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $28.48 | 2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.96 | 2025 | Xifaxan |
| Genentech USA, INC. | $24.50 | 2021 | |
| Corium, LLC | $24.27 | 2023 | Azstarys |
| Sk Life Science, INC. | $23.50 | 2023 | |
| Glaxosmithkline, LLC. | $23.23 | 2023 | Benlysta, Nucala |
| Nestle Healthcare Nutrition INC. | $20.30 | 2022 | |
| Lundbeck LLC | $18.73 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $18.32 | 2022 | |
| Ucb, INC. | $17.63 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $17.46 | 2024 | Evkeeza |
| Abbott Laboratories | $16.14 | 2024 | Eterna |
| Inspire Medical Systems, INC. | $14.99 | 2023 | Inspire |
| Xeris Pharmaceuticals, INC. | $14.28 | 2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Galler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.